Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive versus standard Remicade induction in pediatric steroid-dependent moderate to severe ulcerative colitis
MOH_2017-08-16_000364Phase 4Recruiting
- Sponsor
- ד"ר עמית אסא
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in autoimmune colitis (2 arms), sponsored by ד"ר עמית אסא. Primary endpoint: Efficacy of intensive infliximab treatment versus standard treatment. Started Jun 2017; status: recruiting.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-08-16_000364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-16_000364.